Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1682—Processes
  • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• the present invention is directed to a multiparticulate, modified release solid dispersion formulation, to a unit dosage of the same, as well as to a process for the preparation thereof.
• the invention also concerns the use of a multiparticulate, modified release solid dispersion formulation for the manufacture of a medicament for the treatment of gastric acid related diseases.
• Solubility of a drug in the gastrointestinal fluids and its permeability through the cell membrane determines its oral bioavailability (Leuner and Dressman, Eur. J. Pharm. Biopharm 50, (2000) 47-60).
• the dissolution rate in the lumen is the rate-limiting step.
• Particle size reduction, solubilization, and salt formation are commonly used formulation methods to improve the dissolution rate.
• Gel matrix tablets is a common drug form for modified release. The release rate is controlled either by erosion or by the diffusion of drug molecules in the swelled polymer matrix, which is the reason why drug solubility in the matrix material has great influence on the release rate.
• matrix tablets are also that they cannot always be divided, whereas multiparticulate tablets can be divided.
• Solid dispersions have been studied as a possibility to control the drug release rate (Aceves et al., Int. J. Pharm. 195, (2000) 45-53).
• Solid dispersion is a dispersion of one or more active ingredients in an inert carrier or matrix at solid state, prepared by the melting (fusion), solvent or melting-solvent method (Chiou and Riegelman., J. Pharm. Sci. 60, (1971) 1281-1302).
• Chiou and Riegelman have classified the solid dispersions into following groups: Eutetic mixtures; solid solutions; glass solutions and glass suspensions; amorphous precipitations in crystalline carrier; and combinations of those above.
• melt processing was presented for the first time by Segikuchi, K. and Obi, N. in 1961, in Chem. Pharm. Bull. 9 (1961), 866-872 to prepare solid dispersions.
• melt method a physical mixture of the carrier and the drug is melted and then solidified. Cooling leads to supersaturation, but due to solidification the dispersed drug is trapped in to the carrier matrix.
• Melt method is often recommended, because no organic solvents are needed, so it is often less costly and better for the environment than the solvent method. However, it is not a suitable manufacturing method for thermolabile drugs. Thermal degradation, sublimation and polymorphic transformations may also occur during fusion (Goldberg et al, J. Pharm. Sci.54, (1965) 1145-1148).
• Solid dispersions can be prepared of lipophilic matrix materials.
• the release rate is adjusted by varying the drug-excipient ratio.
• the amount of drug released increases with increased loading (Bodmeier et al, Drug. Dev. Ind. Pharm. 16 (9), (1990) 1505-1519).
• different polymers have been used to control drug release rate from solid dispersions. Ozeki et al.
• US 6, 132, 772 discloses an oral, extended release solid pharmaceutical composition
• an oral, extended release solid pharmaceutical composition comprising polyethylene glycol having a molecular weight of at least 1000, a drug having a solubility of less than 0.1 % by weight in water at 20 °C and a hydrophilic gel-forming polymer having a mean molecular weight of at least 20 000.
• US 5,965,163 discloses a solid dosage form comprising a plurality of particles.
• the drug may according to this document be soluble or water insoluble.
• US 5,405,617 discloses the preparation of carrier matrices and spray congealed powders comprising an admixture of aliphatic or fatty acid esters and pharmaceutical actives which can be compressed into tablet and caplet dosage form.
• US 4,629,621 discloses a sustained release preparation of bioactive material having erodible characteristics.
• Stearic acid (C-18) is the most commonly used of the fatty acids in pharmaceutical products. In oral pharmaceutical formulations, it is mainly used as a tablet lubricant in small concentrations and as a binder (The Handbook of Pharmaceutical Excipients, 3 rd Ed. AphA, (2000) 665). Stearic acid has also been used as a controlled release matrix excipient in spray congealing (Rodriguez et al, Int. J. Pharm. 183, (1999) 133-143).
• the drug substances used by Rodriguez were theophylline having a water solubility at 25 °C of 8.3 mg/ml, and fenbufen having a water solubility at 25 °C of 0.11 mg/ml.
• Outline of the invention are theophylline having a water solubility at 25 °C of 8.3 mg/ml, and fenbufen having a water solubility at 25 °C of 0.11 mg/ml.
• the object of the present invention is to provide a pharmaceutical formulation of a drug substance having a pH-dependent solubility in water.
• the present invention is directed to a multiparticulate, modified release solid dispersion formulation, comprising
• R 4 is (a) H
• R and R are the same or different, selected from any one of
• At least one hydrophobic matrix former which is a meltable, non-swelling amphiphilic lipid having a water-solubility below 1 mg/g
• modified release is herein defined as a formulation that releases less than 90% if its drug contents during the first three hours of the release.
• hydrophobic matrix former as used herein, is defined such that one hydrophobic matrix former can be used alone, or in an alternative embodiment of the invention a mixture of hydrophobic matrix formers may be used.
• hydrophilic matrix former as used herein, is defined such that one hydrophilic matrix former can be used alone, or in an alternative embodiment of the invention a mixture of hydrophilic matrix formers may be used.
• solid dispersion is herein defined as a dispersion of the active compound of the formula I in an inert carrier or matrix at solid state.
• Solid dispersions are more particularly defined herein as eutetic mixtures, solid solutions, glass solutions or glass suspensions, amorphous precipitations in crystalline carrier or combinations thereof.
• the solubility of the substances used in accordance with the present invention is pH-dependent.
• pH-dependent solubility is in accordance with the present invention defined so as that the solubility of the drug substance in water is higher in lower pH, and lower in higher pH, more specifically at least 2 mg/ml at pH ⁇ 2 and lower than 1 mg/ml at pH > 4 at room temperature, i.e. at a temperature of about 23 -25°C.
• multiparticulate formulation as used in accordance with the present invention is defined as a formulation comprising individual units of the drug substance, the hydrophobic matrix former and the hydrophilic matrix former, compressed into e.g. one single tablet.
• hydrophobic matrix formers are in accordance with the present invention water- insoluble, non-swelling fatty acids having a melting point above 50 °C, more particularly a melting point up to 55 °C.
• a specific fatty acid useful in accordance with the present invention is myristic acid.
• hydrophilic matrix formers are in accordance with the present invention meltable, water soluble excipients which are solid at room temperature, such as polyethylene oxides; polyethylene glycols; and polyethylene oxide and polypropylene oxide block-co-polymers, e.g. poloxamers.
• polyethylene oxides polyethylene glycols
• polyethylene oxide and polypropylene oxide block-co-polymers e.g. poloxamers.
• poloxamers useful in accordance with the present
• ® invention are poloxamer 188, also known under the trade name Pluronic F68 , and
• ® and Pluronic F127 are commercially available from BASF.
• Specific examples of polyethylene glycols useful in accordance with the present invention are PEG 4000, known
• Any poloxamer and PEG which are solid at room temperature may be used in accordance with the present invention.
• a comprehensive list of poloxamers and PEG's useful in accordance with the present invention can be found in Handbook of Pharmaceutical Excipients 3rd Ed., American Pharmaceutical Association and Pharmaceutical Press (2000), Washington, 665, which is hereby incorporated by reference, but which list however should not in any way be interpreted as exhaustive.
• other hydrophilic excipients which are miscible with the hydrophobic matrix formers as melts are useful in accordance with the present invention.
• the weight ratio of hydrophobic matrix former/ hydrophilic matrix former is > 1, the excess amount of the hydrophobic matrix providing a sustained release effect.
• the total amount of the compound of the formula I is below about 40 % by weight. In a further aspect of the invention the total amount of the compound of the formula I is 30-40 % by weight, and in still a further embodiment of the invention the total amount of the compound of the formula I is 20-30 % by weight.
• unit dosage form is herein defined as a composition where the amount of active compound of the formula I is administered as one single tablet, capsule or other suitable form in accordance with the present invention.
• Cj-Cg alkyl denotes a straight or branched alkyl group having from 1 to 6 carbon atoms.
• Examples of said C ⁇ C6 alkyl include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl and straight- and branched-chain pentyl and hexyl.
• halogen includes fluoro, chloro, bromo and iodo.
• the drug substance used in accordance with the present invention are both the pure enantiomers, racemic mixtures and unequal mixtures of two enantiomers. It should be understood that all the diastereomeric forms possible (pure enantiomers, racemic mixtures and unequal mixtures of two enantiomers) are within the scope of the present invention as the active drug substance, as well as derivatives of the compounds of the Formula I which have the biological function of the compounds of the Formula I, such as prodrugs.
• derivatives of compounds of formula I may not possess pharmacological activity as such, they may be administered orally and thereafter metabolised in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs”. Prodrugs of compounds of formula I are also within the scope of the invention. Depending on the process conditions the end products of the Formula I are obtained either in neutral or salt form. Both the free base and the salts of these end products are within the scope of the invention.
• the active drug substance is a compound of the formula I wherein R 1 is CH 3 or CH 2 OH; R 2 is CH 3 or CH 2 CH 3 ; R 3 is CH 3 or CH 2 CH 3 ; R 4 is CH 3 or CH 2 CH 3 ; R 5 is H, Br, CI, or F.
• the active drug substance of the formula I is a compound selected from any one of
• 6-carboxamide or a pharmaceutically acceptable salt thereof.
• the active drug substance of the formula I is a compound selected from any one of
• the pharmaceutical formulation according to the present invention is useful particular for the inhibition of gastric acid secretion.
• one aspect of the present invention is the use of a multiparticulate, modified release formulation as claimed and described herein, for the manufacture of a medicament for the inhibition of gastric acid secretion.
• Another aspect of the present invention is a method for the inhibition of gastric acid secretion, whereby a multiparticulate, modified release formulation as claimed and described herein, is administered to a patient in need of such gastric acid secretion inhibition.
• the typical daily dose of the active substance according to formula I above varies within a wide range and will depend on various factors such as for example the individual requirement of each patient and the disease.
• the formulation according to the invention is administered orally, and dosages will be in the range of from 5 to 1000 mg per day of active substance.
• the multiparticulate, modified release formulation according to the present invention may be formulated into a unit dosage form, preferably as a tablet, which may also comprise standard excipients known to the skilled person in the art of tablet formulation. Examples of such excipients are fillers, binders, disintegrants and lubricants, but this list should however not be interpreted as being exhaustive.
• the multiparticulate, modified release solid dispersion formulation according to the present invention provides the possibility of formulating drug substances of the formula I, said drug substances having a pH-dependent solubility in water.
• the novel formulation is particularly useful when formulated into a tablet, since it may also provide improved chances of dividing the tablet without disturbing the release rate of the active drug substance.
• spray congealing or spray chilling as it is also called, the melted mass is atomized into droplets, which solidify quickly in cool air (Killeen, Pharm. Eng., July/August 1993, 56-64).
• the process differs from spray drying in that in spray drying the main action is evaporation of solvent caused by warm air, whereas in spray congealing it is a phase change from liquid to solid.
• the spray congealing process used in accordance with the present invention comprises the following steps:
• the produced particles can then be further formulated into tablets or filled into capsules.
• the atomization into droplets can be done with different techniques, such as with a capillary nozzle, with a pneumatic nozzle, with an ultrasonic nozzle, with a hydraulic nozzle, with electrospraying, with rotary atomization, and preferably with a pneumatic nozzle using warm air as atomization gas.
• the solidification of droplets can take place in liquid nitrogen, in or on carbondioxide ice or in air with a temperature lower than the melting point of the droplets.
• the particles may be collected into a vessel directly, or with a cylinder connected to a cyclone.
• the resulted particles are smaller than 300 ⁇ m, preferably spherical.
• the drug is in the particles present in the form of a solid dispersion.
• Additives may be added into the melt prior to the atomization.
• examples of such additives are surface active agents, excipients increasing viscosity, and buffering agents, but this list should however not in any way be interpreted as limiting the invention.
• the resulted particles were spherical and smaller than 300 ⁇ m in size, as seen in Scanning Electron Micrograph (SEM).
• step I The amount of 3 g of particles prepared in step I above, were blended with 5.85 g microcrystalline cellulose and 0.016 g sodium stearyl fumarate in a Turbula mixer of the type 72C, Willy A. Bachofen AG Maschinenfabrik, Basle, Switzerland, for 10 minutes.
• This mixture was compressed by using an excentric tablet press Korsch EK-0 into 450 mg tablets using 11.3 mm flat punches with a maximum compression force of 5.0-5.6 kN.
• the breaking force of resulting tablets was measured by using a Schleuniger tablet hardness tester 4M, Dr. Schleuniger Productronic AG, Solothurn, Switzerland. The breaking force of resulting tablets was within the range 139-168 N.
• the resulted particles were spherical and smaller than 300 ⁇ m in size, as seen in Scanning Electron Micrograph (SEM).

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Cosmetics (AREA)
• Steroid Compounds (AREA)
• Hydrogenated Pyridines (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
• Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (6)

Applications Claiming Priority (4)

Related Child Applications (1)

Publications (1)

Family

ID=26655389

Family Applications (2)

Family Applications After (1)

Country Status (18)

Cited By (4)

Families Citing this family (22)

Citations (5)

Family Cites Families (8)

• 2002
  • 2002-02-08 IL IL15707502A patent/IL157075A0/xx unknown
  • 2002-02-08 MX MXPA03007092A patent/MXPA03007092A/es active IP Right Grant
  • 2002-02-08 CN CNA028049144A patent/CN1491104A/zh active Pending
  • 2002-02-08 US US10/467,723 patent/US20040067252A1/en not_active Abandoned
  • 2002-02-08 BR BR0206825-7A patent/BR0206825A/pt not_active IP Right Cessation
  • 2002-02-08 NZ NZ526993A patent/NZ526993A/en unknown
  • 2002-02-08 AU AU2002228579A patent/AU2002228579B2/en not_active Ceased
  • 2002-02-08 JP JP2002563916A patent/JP2004518709A/ja active Pending
  • 2002-02-08 DK DK02710645T patent/DK1368006T3/da active
  • 2002-02-08 US US10/467,900 patent/US20040067256A1/en not_active Abandoned
  • 2002-02-08 EP EP02710645A patent/EP1368006B1/en not_active Expired - Lifetime
  • 2002-02-08 CA CA002434542A patent/CA2434542A1/en not_active Abandoned
  • 2002-02-08 AT AT02710645T patent/ATE324871T1/de not_active IP Right Cessation
  • 2002-02-08 WO PCT/SE2002/000227 patent/WO2002064118A1/en not_active Ceased
  • 2002-02-08 JP JP2002563914A patent/JP2004518708A/ja active Pending
  • 2002-02-08 ES ES02710645T patent/ES2261643T3/es not_active Expired - Lifetime
  • 2002-02-08 EP EP02711597A patent/EP1361868A1/en not_active Withdrawn
  • 2002-02-08 PT PT02710645T patent/PT1368006E/pt unknown
  • 2002-02-08 CN CNA028049063A patent/CN1491105A/zh active Pending
  • 2002-02-08 WO PCT/SE2002/000228 patent/WO2002064121A1/en not_active Ceased
  • 2002-02-08 CA CA002434835A patent/CA2434835A1/en not_active Abandoned
  • 2002-02-08 KR KR10-2003-7010577A patent/KR20040058103A/ko not_active Abandoned
  • 2002-02-08 DE DE60211130T patent/DE60211130T2/de not_active Expired - Fee Related
  • 2002-02-08 NZ NZ526994A patent/NZ526994A/en unknown
• 2003
  • 2003-08-12 NO NO20033564A patent/NO20033564L/no not_active Application Discontinuation
• 2007
  • 2007-05-14 US US11/748,366 patent/US20080118560A1/en not_active Abandoned

Patent Citations (6)

Also Published As

Similar Documents

Legal Events